^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

MA13.08 - A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients With Advanced NSCLC (NCI 10327): Results from Dose Escalation

Published date:
07/12/2022
Excerpt:
Of the 8 patients evaluable for response (1 PR/4 SD/3 PD), 5 patients had tumor shrinkage including a patient with KRAS/KEAP1 mutant LUAD (SD) and 1 patient with LUSC harboring an NFE2L2 mutation (PR) at DL2.The RED for sapanisertib + telaglenastat is DL1 (sapanisertib 2mg po qd, telaglenastat 800mg po bid). The majority of evaluable patients had tumor shrinkage including a PR in a patient with LUSC harboring an NFE2L2 mutation. Sapanisertib and telaglenastat is safe and tolerable at the RED.
Trial ID: